CERUS CORP. overview

Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2023. Recent highlights include: Second quarter 2023 total revenue of $47.7 million was comprised of total product revenue of $38.9 million and government contract revenue of $8.9 million. Received positive feedback for INTERCEPT Red Blood Cells CE Mark submission in clarification meeting with EU competent authority, the Dutch Medicines Evaluation Board (CBG), supporting possible CE Mark...

Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2023 financial results will be released on Wednesday, August 2, 2023, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the...

Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and a lunch symposium at the 33 rd Regional International Society of Blood Transfusion (ISBT) Congress, taking place in Gothenburg, Sweden, from June 17 through June 21. Transfusion medicine experts and professionals from around the world attend the ISBT Congress. This year marks the first time the conference has taken place in person since 2019. The following is a select list of presentations and abstracts of interest for...

Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2023. In 2005, the World Health Assembly designated June 14 as World Blood Donor Day to recognize and thank blood donors across the world for their important contributions to the global blood supply. For 2023, the focus of this day is on those patients who rely on blood products over their lifetime, and the donors who make this possible, with the slogan “Give blood, give plasma, share life, share...

Cerus Corporation (Nasdaq: CERS) today announced that it has been awarded an additional $8.7 million contract amendment to the original $9.1 million contract by the U.S. Department of Defense (DoD) Industrial Base Analysis and Sustainment (IBAS) program for the development of pathogen reduced, lyophilized cryoprecipitate (“LyoCryo”) to treat bleeding due to trauma. Cerus’ LyoCryo product is being designed for shelf stability, rapid availability, and portability, enabling administration to...

Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2023. Recent highlights include: First quarter 2023 total revenue of $38.5 million was comprised of ( in thousands, except %) : Three Months Ended March 31, Change 2023 2022 $ % Product Revenue $ 30,974 $ 37,444 $ (6,470 ) -17 % Government Contract Revenue 7,502 5,576 1,926 35 % Total Revenue $ 38,476 $ 43,020 $ (4,544 ) -11 % The Company is reiterating its full-year 2023 annual product...

Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2023 financial results will be released on Thursday, May 4, 2023, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus...

Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and full year ended December 31, 2022. Recent highlights include: Fourth quarter 2022 and full-year 2022 total revenue was comprised of ( in thousands, except % ) : Three Months Ended Twelve Months Ended December 31, Change December 31, Change 2022 2021 $ % 2022 2021 $ % Product Revenue $ 44,034 $ 39,865 $ 4,169 10 % $ 162,048 $ 130,859 $ 31,189 24 % Government Contract Revenue 7,287 10,223 (2,936 ) (29 %)...